for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Elanco Animal Health Inc

ELAN.N

Latest Trade

26.67USD

Change

0.32(+1.21%)

Volume

372,225

Today's Range

26.39

 - 

27.00

52 Week Range

25.25

 - 

35.46

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
26.35
Open
26.73
Volume
372,225
3M AVG Volume
86.25
Today's High
27.00
Today's Low
26.39
52 Week High
35.46
52 Week Low
25.25
Shares Out (MIL)
373.00
Market Cap (MIL)
9,828.66
Forward P/E
24.72
Dividend (Yield %)
--

Next Event

Elanco Animal Health Inc Annual Shareholders Meeting

Latest Developments

More

Elanco Animal Health Q3 Adjusted Earnings Per Share $0.30 Including Items

Elanco Intends To Eliminate Approximately 250 Positions Across Multiple Locations And Functions

Elanco Animal Health CEO Jeffrey N Simmons Reports Open Market Purchase Of 75,750 Shares At Average Price Of $26.55 On Sept 4

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Elanco Animal Health Inc

Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.

Industry

Biotechnology & Drugs

Contact Info

2500 Innovation Way N

https://www.elanco.com/

Executive Leadership

R. David Hoover

Independent Chairman of the Board

Jeffrey N. Simmons

President, Chief Executive Officer, Director

Todd S. Young

Chief Financial Officer, Executive Vice President

Michael-Bryant Hicks

Executive Vice President, General Counsel, Corporate Secretary

David S. Kinard

Executive Vice President of Human Resources

Key Stats

2.38 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

3.1K

2019(E)

3.1K
EPS (USD)

2018

1.180

2019(E)

1.066
Price To Earnings (TTM)
103.12
Price To Sales (TTM)
3.19
Price To Book (MRQ)
1.79
Price To Cash Flow (TTM)
24.66
Total Debt To Equity (MRQ)
43.01
LT Debt To Equity (MRQ)
42.56
Return on Investment (TTM)
1.17
Return on Equity (TTM)
1.04

Latest News

Latest News

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health <ELAN.N> agreed to buy Bayer's <BAYGn.DE> veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

Elanco to buy Bayer's animal health unit for $7.6 billion

Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space.

UPDATE 1-Bayer, Elanco aiming to reach animal-health deal next week - Bloomberg

Germany's Bayer AG and U.S. drug firm Elanco Animal Health Inc aim to reach an agreement to combine their pet-health businesses as soon as next week, Bloomberg reported https://www.bloomberg.com/news/articles/2019-08-07/elanco-bayer-said-aiming-to-reach-animal-health-deal-next-week...

Bayer, Elanco aiming to reach animal-health deal next week - Bloomberg

Germany's Bayer AG <BAYGn.DE> and U.S. drug firm Elanco Animal Health Inc <ELAN.N> aim to reach an agreement to combine their pet-health businesses as soon as next week, Bloomberg reported on Wednesday, citing people with knowledge of the matter.

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

Bayer <BAYGn.DE> has approached U.S. drug firm Elanco Animal Health <ELAN.N> to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up